Biogen’s Post

Amyloid and Tau models recapitulate pathological processes found in patients with Alzheimer’s Disease, including protein aggregation, neuroinflammation, neurodegeneration, and cognitive impairments. The key to understanding a therapeutic compound’s effect on amyloid-beta pathology-induced neuroinflammation, is to use robust and reliable models that consistently show progressive plaque pathology, such as the APP/PS1 (ARTE10) model. View example histopathological data here: https://lnkd.in/eKhpC6nX To view other models, browse through InnoSer's portfolio here: https://lnkd.in/ejQFTpA6 👉 Do you have specific questions relating to our Alzheimer's disease models? Our InnoSer neurology team is exhibiting (booth #22) at the upcoming #ADPD2024 conference and will be happy to answer any of your questions relating to Alzheimer's or other neurodegenerative disease models.

Adriana González-Caballero joined her Kx Advisors and BGB Group colleagues reporting on findings from the annual Alzheimer's Association International Conference in Philly as one of our distinguished neurology experts. In partnership with Chris Waybill, Chloe Weiser, and BGB Group colleagues Juan M. Valdez Capuccino, Ph.D. and Exene Anderson, PhD, Adriana is digging a bit deeper into one of the topics that came up - diagnostic hurdles and blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM

Sano CEO Patrick Short and Dr. Andrea Gropman, an expert in pediatric neurology, genetics, and inborn errors of metabolism, recently sat down for a fascinating conversation on the impact of genetics on modern medical practice. In the clip below, Dr. Gropman discusses industry areas she's keen to see improve. Feel free to check out the full webinar here: https://lnkd.in/emNSfvfY. #PrecisionMedicine #Genomics #ClinicalTrials

Join our webinar on June 6th at 11:00 am MDT, "Using Proteomics to Advance Understanding of Alzheimer’s Disease," featuring Dr. Erik Johnson, Assistant Professor at Emory University's Department of Neurology.     Discover breakthroughs in Alzheimer's research as Dr. Johnson navigates through dynamic brain changes and biomarker discovery using a proteomic approach.      Explore the potential of affinity-based proteomics in identifying reliable biomarkers and gain insights into intricate networks like proteostasis and the matrisome. Don't miss this opportunity to learn from a leading expert contributing to the fight against Alzheimer's disease.     Register now here: https://lnkd.in/gDbrrwms     #AlzheimersResearch #Proteomics #Webinar 

In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/gnhdGAiZ

A paper published in Nature Reviews Neurology, discusses suspected non-AD pathophysiology (SNAP), which is common in individuals with MCI and normal cognition (NC). People with NC-SNAP have a low risk of cognitive decline over 7 years, and longer follow-up studies are needed to demonstrate whether they will eventually show faster cognitive decline than those with NC and normal biomarkers. People with MCI-SNAP have an increased risk of developing clinical AD dementia at follow-up (annual conversion rate 7% compared with 1% for MCI with normal biomarkers). This finding suggests that SNAP might partly reflect a lack of sensitivity of biomarkers to detect early amyloid pathology, although misdiagnosis at follow-up is another possibility. The frequency of AD genetic risk factors in A− T individuals with SNAP is similar to that in control individuals and lower than in those with AD. This finding is mainly driven by a lower frequency of APOE ε4 in SNAP than in AD. CSF proteomics have shown that people with SNAP have increased CSF levels of Aβ38 and Aβ40 compared with patients with AD and control individuals, possibly reflecting the effects of tau pathology without marked amyloid aggregation. A distinguishing feature in people with MCI-SNAP is a decrease in CSF levels of proteins that are highly expressed in the choroid plexus, suggesting a role for this structure in MCI-SNAP. Neuropathological studies have indicated a range of possible neuropathologies associated with SNAP, including TDP43-related pathologies (LATE and FTLD-TDP), tau pathology (PART, AGD and PSP), LBD and cerebrovascular pathology. In older individuals, SNAP probably represents a combination of neuropathological lesions. Nature Portfolio Springer Nature Group #neuroscience #neurology #neurologicaldisorders #neurodegenerativedisorders #alzheimersdisease #alzheimer #cognitivedecline #dementia #biomarkers #precisionmedicine #diagnosis #earlydiagnosis #earlydetection #prediction #SNAP #PART #FTD #ALS #Parkinsonsdisease #AGD #PSP #LATE #neuropathology #brain #brainresearch #clinicalresearch #MCI #cognition #amyloid #pathophysiology #riskfactors #classification #differentialdiagnosis

In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/eteEwcaG

In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/gc_S7eiv

Can't we increase not find a solid state electrolyte that would act as a reducer for depolarization of cell membrane like the new lithium batteries? I don't really know anything about science, but I like to imagine possibilities. 😀 #houseoflovingawareness #coloradomentalwellnessinitiative #willojontv #neurology #science #mentalhealth #mentalhealthmatters #mentalwellness #americanspiritsthemovie

In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/gfb4FUuj